BACKGROUND: The main objective of this randomized, double-blind, parallel-group, comparative study was to assess the efficacy and safety of rupatadine 10 mg (R10) and 20 mg (R20) administered once-daily for two weeks compared with those of loratadine 10 mg (L10) in the treatment of seasonal allergic rhinitis (SAR). METHODS: A total of 339 SAR patients were randomized to receive R20 (111 patients), R10 (112 patients) or L10 (116 patients). The main efficacy variable was the mean total daily symptom score (mTDSS) based on the daily subjective assessment of the severity of rhinitis symptoms--rhinorrhea, sneezing, nasal itching, nasal obstruction, conjunctival itching, tearing and pharyngeal itching--recorded by patients. RESULTS: The mTDSS was significantly lower in the groups treated with R20 (0.80 +/- 0.46) and R10 (0.85 +/- 0.52) than in the group treated with L10 (0.92 +/- 0.51) by protocol analysis (p = 0.03) but not by intention-to-treat analysis. The secondary variables used to assess efficacy (mDSS, DSSmax, CSS and TCSS) also showed significantly milder symptoms in patients treated with R20 and R10, particularly in sneezing and nasal itching. All treatments were well tolerated and no serious adverse events were recorded. Headache was the most frequent non-serious adverse event, and these did not show significant differences between treatments at similar dose levels. Somnolence was more frequent in R20 than in the other two groups. CONCLUSIONS: The present results suggest that rupatadine 10 mg a day may be a valuable and safe alternative for the symptomatic treatment of seasonal allergic rhinitis.
RCT Entities:
BACKGROUND: The main objective of this randomized, double-blind, parallel-group, comparative study was to assess the efficacy and safety of rupatadine 10 mg (R10) and 20 mg (R20) administered once-daily for two weeks compared with those of loratadine 10 mg (L10) in the treatment of seasonal allergic rhinitis (SAR). METHODS: A total of 339 SAR patients were randomized to receive R20 (111 patients), R10 (112 patients) or L10 (116 patients). The main efficacy variable was the mean total daily symptom score (mTDSS) based on the daily subjective assessment of the severity of rhinitis symptoms--rhinorrhea, sneezing, nasal itching, nasal obstruction, conjunctival itching, tearing and pharyngeal itching--recorded by patients. RESULTS: The mTDSS was significantly lower in the groups treated with R20 (0.80 +/- 0.46) and R10 (0.85 +/- 0.52) than in the group treated with L10 (0.92 +/- 0.51) by protocol analysis (p = 0.03) but not by intention-to-treat analysis. The secondary variables used to assess efficacy (mDSS, DSSmax, CSS and TCSS) also showed significantly milder symptoms in patients treated with R20 and R10, particularly in sneezing and nasal itching. All treatments were well tolerated and no serious adverse events were recorded. Headache was the most frequent non-serious adverse event, and these did not show significant differences between treatments at similar dose levels. Somnolence was more frequent in R20 than in the other two groups. CONCLUSIONS: The present results suggest that rupatadine 10 mg a day may be a valuable and safe alternative for the symptomatic treatment of seasonal allergic rhinitis.
Authors: Antonio Valero; Iñaki Izquierdo; Marek L Kowalski; Glenis K Scadding; Jean Bousquet; Joaquim Mullol Journal: Allergy Asthma Clin Immunol Date: 2020-04-23 Impact factor: 3.406
Authors: Joaquim Mullol; Iñaki Izquierdo; Kimihiro Okubo; Giorgio Walter Canonica; Jean Bousquet; Antonio Valero Journal: Clin Transl Allergy Date: 2019-10-09 Impact factor: 5.871
Authors: Olavo de Godoy Mion; Regis A Campos; Martti Antila; Priscila Bogar Rapoport; Nelson Rosario; João Ferreira de Mello Junior; Roberto Eustáquio Santos Guimarães; Marcos Mocellin; Giovanni Di Gesu; Dirceu Solé; Luc Wexler; João Ferreira de Mello; Fábio Morato Castro; Maria Letícia Chavarria Journal: Braz J Otorhinolaryngol Date: 2009 Sep-Oct